PHARMACY

Mylan expands women’s healthcare portfolio with Famy Care acquisition

BY Ryan Chavis

PITTSBURGH and MUMBAI, India — Mylan announced that it will acquire certain businesses from specialty women's healthcare company Famy Care Limited for $750 million, with additional contingent payments of up to $50 million. 
 
Famy Care is a global leader in generic oral contaceptive products and its acquisition by Mylan makes it a leader in the hormonal contraceptives market, Mylan said. The transaction is expected to close in the second half of 2015. 
 
"In 2008, Mylan established a partnership with Famy Care, significantly enhancing its presence in the women's health care segment in the United States and other developed country markets. With today's acquisition, we are building on this successful partnership and further accelerating our global growth in this important therapeutic area," said Mylan CEO Heather Bresch.
 
The transaction will complement the company's pending acquisition of Abbot's non-U.S. developed markets specialty and branded generics business, which also contains a women's healthcare portfolio. 
 
"By adding this vertically integrated business and globalizing our women's healthcare platform, we are creating the right foundation to become a leader in this growing, attractive sector. Famy Care brings us a broad portfolio, strong technical capabilities and dedicated hormone manufacturing, which complement Mylan's powerful global commercial footprint and supply chain infrastructure," said Mylan president Rajiv Malik. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Prezcobix from Janssen Therapeutics granted FDA approval

BY Ryan Chavis

 

TITUSVILLE, N,J. — Janssen Therapeutics on Thursday announced that the Food and Drug Administration has approved its Prezcobix (darunavir 800 mg/cobicistat 150 mg) tablets. The drug is used to treat human immunodeficiency virus in combination with other antiretovirals for treatment-naïve and treatment-experienced adults with no darunavir resistance-associated substitutions, according to the company.
 
The once-daily, fixed-dose Prezcobix contains 800 mg of darunavir — marketed as Prezista in the United States — and 150 mg of cobicistat, which is a pharmockinetic enhancer (sometimes referred to as a "boosting" agent) that is developed and marketed as Tybost by Gilead Sciences. 
 
“Additional options remain an important medical priority to meet the diverse needs of those living with and managing this disease,” said Karen Tashima, M.D., professor of medicine in the division of infectious diseases, Brown University, director of HIV Clinical Studies, Miriam Hospital, and a lead investigator in the GS-US-216-0130 study. “This approval gives physicians the option of a darunavir-based fixed-dose combination tablet to treat adults living with the HIV-1 infection, which can help reduce the number of pills in their overall treatment regimen.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Fruth Pharmacy implements Innovation’s PharmASSIST Symphony workflow technology

BY Antoinette Alexander

JOHNSON CITY, N.Y. — Innovation, makers of PharmASSIST pharmacy automation solutions, has announced that Fruth Pharmacy has purchased the firm’s PharmASSIST Symphony workflow management and process optimization software for a new central fill site in Nitro, W. Va.
 
The central fill site will process most of the refill prescriptions for the retail chain’s 26 pharmacies throughout West Virginia and Ohio.

“Our goal is to launch a new central fill site to help ease the burden of prescription filling on our in-store pharmacies and free up staff to better provide patient counseling and immunization services,” stated Tim Weber, VP of Fruth Pharmacy. “We have a unique scenario in which we can redeploy existing in-store robotic dispensing and pharmacy management technologies. We can then augment these key components with the Symphony high-volume workflow software, which will serve as the control center for the site’s prescription filling, order management, packaging, and delivery.”

Fruth customers can still expect same-day service at their local pharmacy. Weber said in most cases a patient’s refill will be enrolled in an auto-fill program and be ready and waiting for them at the store two-to-three days before the prescription is due to run out.

“Innovation was a great fit for us because of their willingness to work with our existing technologies and bring it all together for us,” stated Weber. “We are also very impressed with their Symphony high-volume capabilities, and are looking forward to bringing the central fill site to fruition.”

“The sheer flexibility of our various automation and software solutions, along with our professional services skill set, enables us to work with any type of pharmacy in any situation,” added Doyle Jensen, VP, global business development. “In this case, we’re helping Fruth Pharmacy leverage their investment in existing technologies and augment them with next generation, high-volume workflow management.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?